Burning Rock Biotech (BNR) | Stock Overview & Key Data
Burning Rock Biotech Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $41.69 on January 22, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 221.68M Micro-cap | -32.63% | -43.92% | -62.40% | -55.60% | -51.02% | 200.65% | 285.12% | -65.34% | -62.16% | -62.16% | -62.16% | |
|
Thermo Fisher
TMO
|
174.55B Large-cap | 7.56% | 4.21% | -5.21% | -16.94% | -18.64% | 22.27% | -5.31% | 9.75% | 222.18% | 684.25% | 1,233.99% |
|
Danaher
DHR
|
126.39B Large-cap | 1.91% | 1.19% | -14.51% | -22.28% | -23.56% | -3.81% | -12.18% | -14.95% | 176.52% | 423.71% | 744.91% |
|
Fonar
FONR
|
118.64M Micro-cap | 0.95% | 0.90% | 2.86% | 32.66% | 3.08% | 31.72% | 13.49% | 5.18% | 16.25% | 827.18% | 55.92% |
|
Biodesix
BDSX
|
107.54M Micro-cap | 4.25% | 37.00% | -1.97% | 97.19% | 139.01% | 170.20% | -39.56% | -94.00% | -93.44% | -93.44% | -93.44% |
|
Oncocyte
OCX
|
65.62M Micro-cap | -4.35% | 47.37% | 24.70% | 6.94% | -13.97% | 87.05% | 41.14% | -93.86% | -92.52% | -95.03% | -95.03% |
Ownership & Short Interest
Calculate Your Burning Rock Biotech Investment Returns
Long-Term Investment Performance Analysis
Burning Rock Biotech stock price in Jun 2020 was $24.63, A $1,000.00 lump sum investment in Burning Rock Biotech made 6 years ago would be worth approximately $352.82 today, representing a negative return of -64.72%. This translates to an annualized return (CAGR) of -15.98%.
5 Years 11 Months Investment Scenario (Jun 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BNR's 52-week high and low?
- In the last 52 weeks, Burning Rock Biotech reached a high of $41.72 (on N/A) and a low of $2.80 (on June 3, 2025).
- What is the market cap and P/E ratio for BNR?
- Curious about Burning Rock Biotech's size and valuation? Its market capitalization stands at 221.68M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.61, and the forward P/E (looking ahead) is -35.60.
- Does BNR pay dividends? If so, what's the yield?
- As for dividends, Burning Rock Biotech isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Burning Rock Biotech's main competitors or similar companies to consider before investing?
When looking at Burning Rock Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO174.55B Healthcare Diagnostics & Research 22.27% -5.31% Danaher
DHR126.39B Healthcare Diagnostics & Research -3.81% -12.18% Fonar
FONR118.64M Healthcare Diagnostics & Research 31.72% 13.49% Biodesix
BDSX107.54M Healthcare Diagnostics & Research 170.20% -39.56% Oncocyte
OCX65.62M Healthcare Diagnostics & Research 87.05% 41.14% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Burning Rock Biotech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Burning Rock Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -9.92%, the Debt to Equity ratio from the most recent quarter is 8.06, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BNR?
- Looking at Burning Rock Biotech's growth, its revenue over the trailing twelve months (TTM) was $79M. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.20%, and quarterly earnings saw a YoY growth of N/A.
- How much of BNR stock is held by insiders and institutions?
- Wondering who owns Burning Rock Biotech stock? Company insiders (like executives and directors) hold about 3.92% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 44.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.